Chronic Obstructive Pulmonary Disease (COPD) Market Report by Types, Treatment Types, Distribution Channels, Countries and Companies Analysis 2026-2034

Chronic Obstructive Pulmonary Disease Market Size and Forecast

Global Chronic Obstructive Pulmonary Disease (COPD) market is projected to grow from US$ 27.53 billion in 2025 to US$ 51.17 billion by 2034, registering a CAGR of 7.13% during 2026–2034. Market expansion is being driven by the rising global burden of COPD, increasing demand for effective long-term disease management, and growing adoption of advanced respiratory care technologies. The integration of digital inhalers and connected respiratory devices is improving medication adherence, treatment monitoring, and patient engagement, while the introduction and approval of next-generation bronchodilators are broadening therapeutic options.

What is Chronic Obstructive Pulmonary Disease and its Uses & Popularity Worldwide

Chronic Obstructive Pulmonary Disease (COPD) is a progressive, long-term lung condition characterized by restricted airflow, breathing difficulties, chronic cough, wheezing, and fatigue. COPD primarily includes emphysema and chronic bronchitis and develops when prolonged exposure to harmful particles damages the airways and lung tissue. Smoking and air pollution are among the most important causes, while occupational exposure to dust, fumes, and chemicals can also contribute.

COPD is not curable, but its symptoms and progression can be managed through inhaled medicines, bronchodilators, oxygen therapy, pulmonary rehabilitation, vaccinations, smoking cessation, and reduction of pollution exposure. These treatments help improve breathing, reduce exacerbations, support daily activities, and enhance quality of life. Worldwide, COPD represents a major healthcare burden. The WHO reports that COPD caused approximately 3.4 million deaths in 2023, making it the third leading cause of death globally and accounting for around 6% of all deaths. Earlier WHO estimates indicated approximately 392 million people were living with COPD in 2019, with about three-quarters residing in low- and middle-income countries.

Key Points on Chronic Obstructive Pulmonary Disease (COPD) in Australia

• 496,000 people: Around 496,000 Australians aged 45 and over (4.8%) were estimated to be living with COPD in 2022.
• COPD increases with age: Prevalence increased from 1.7% among people aged 45–54 to 7.0% among those aged 75 and over in 2022.
• Major disease burden: COPD accounted for 3.7% of Australia’s total disease burden in 2024, including 3.2% of non-fatal burden and 4.1% of fatal burden.
• Leading respiratory burden: COPD accounted for 51% of the total disease burden attributable to respiratory diseases in Australia in 2024.
• 7,437 deaths: COPD was the underlying cause of 7,437 deaths in 2023, equivalent to 28 deaths per 100,000 population and 4.1% of all deaths.
• High hospitalisation burden: During 2023–24, approximately 69,200 hospitalisations had COPD as the principal diagnosis, while 159,000 hospitalisations involved COPD as either a principal or additional diagnosis.
• Emergency-care demand: Australia recorded approximately 61,500 emergency department presentations for COPD in 2024–25, equivalent to a rate of 225 presentations per 100,000 population.
• Significant healthcare expenditure: Australia’s health system spent an estimated A$1.8 billion on COPD in 2023–24, representing 30% of total expenditure on respiratory conditions.
• Smoking is the largest risk factor: In 2024, 65% of the total COPD disease burden was attributable to tobacco use, while 7% was attributable to air pollution and 2% to occupational exposures and hazards. Overall, 74% of COPD burden could potentially have been prevented by reducing these risk exposures.
• Strong geographic and socioeconomic disparities: In 2022, COPD prevalence among people aged 45 and over was 7.3% in outer regional and remote areas, compared with 4.2% in major cities. Prevalence was also 9.0% in the most socioeconomically disadvantaged areas, versus 2.4% in the least disadvantaged areas.

Source: Australian Institute of Health and Welfare (AIHW) – Chronic obstructive pulmonary disease, updated February 2026.

Growth Drivers of the Chronic Obstructive Pulmonary Disease Market

Rising Global Burden of COPD

The increasing prevalence and mortality associated with COPD are major factors driving demand for diagnostic technologies, inhaled medicines, oxygen systems, pulmonary rehabilitation, and other disease-management solutions. The WHO reported that COPD caused 3.4 million deaths worldwide in 2023, representing approximately 6% of all global deaths and making COPD the third leading cause of death globally. Earlier global estimates also identified approximately 392 million COPD cases in 2019, demonstrating the enormous patient population requiring long-term management. The disease burden is particularly significant in low- and middle-income countries, where nearly 90% of COPD deaths among people younger than 70 occur. Aging populations are further increasing the number of people susceptible to chronic respiratory disorders because COPD symptoms commonly develop from mid-life onward. Rising awareness of respiratory symptoms, improvements in spirometry and other diagnostic approaches, and greater access to specialized pulmonary care are encouraging earlier detection. Pharmaceutical companies are also developing improved inhaled therapies and combination treatments to manage symptoms and reduce exacerbations. As healthcare systems increasingly prioritize chronic disease management and prevention of avoidable hospitalizations, the growing COPD patient population is expected to sustain demand for COPD-related products and services worldwide.

High Prevalence of Tobacco Smoking and Exposure to Air Pollution

Continued exposure to tobacco smoke and air pollution is a major driver of the global COPD burden and consequently supports demand for treatment and disease-management products. The WHO reports that tobacco smoking accounts for more than 70% of COPD cases in high-income countries, while it contributes approximately 30–40% of cases in low- and middle-income countries. Around 1.2 billion people worldwide use tobacco, and approximately 80% of tobacco users live in low- and middle-income countries. Household air pollution is another major risk factor, particularly in developing economies. The WHO estimates that approximately 2.1 billion people globally cook using open fires or inefficient stoves powered by biomass, coal, or kerosene, exposing households to harmful pollutants. Long-term exposure to cigarette smoke, second-hand smoke, industrial fumes, vehicle emissions, and household smoke can damage lung tissue and accelerate respiratory decline. These persistent environmental exposures create a large population at risk of COPD. Consequently, the need for inhalers, bronchodilators, oxygen therapy, pulmonary rehabilitation, diagnostic testing, and other management solutions is expected to remain strong, particularly in regions with high smoking rates and severe air-pollution exposure.

Growing Aging Population and Demand for Long-Term Disease Management

Population aging is another important factor supporting the global COPD market because the disease is strongly associated with cumulative exposure to tobacco smoke, pollution, and occupational hazards over a person’s lifetime. COPD symptoms commonly become apparent from mid-life onward, and older adults frequently require long-term treatment and monitoring. The increasing number of elderly people worldwide is therefore creating a larger population susceptible to chronic respiratory disease. COPD also frequently occurs alongside other chronic conditions, including cardiovascular disease, diabetes, lung cancer, and osteoporosis, increasing healthcare utilization and the complexity of disease management. WHO notes that people with COPD have a higher risk of several other health problems, including heart disease and lung cancer. As healthcare systems move toward integrated and patient-centered chronic disease management, demand is increasing for long-acting bronchodilators, combination inhalers, oxygen equipment, pulmonary rehabilitation, monitoring technologies, and home-based care. Improvements in diagnostic capabilities are also helping healthcare professionals identify respiratory impairment earlier. In addition, greater awareness among older adults regarding persistent cough, breathlessness, and other symptoms is encouraging medical consultation. The combination of demographic aging, multimorbidity, and the need for lifelong disease management is expected to support continued expansion of the COPD treatment and management market.

Challenges of the Chronic Obstructive Pulmonary Disease Market

Underdiagnosis and Limited Access to Diagnosis and Treatment

Underdiagnosis and inadequate access to respiratory healthcare remain significant challenges for the global COPD market, particularly in low- and middle-income countries. COPD diagnosis is generally confirmed using spirometry, a breathing test that measures lung function, but access to spirometry and trained healthcare professionals is limited in many regions. The WHO specifically notes that spirometry is often unavailable in low- and middle-income countries, resulting in missed or delayed diagnoses. This creates a substantial gap between the number of people living with COPD and those receiving appropriate treatment. Earlier WHO estimates found that approximately three-quarters of people with COPD live in low- and middle-income countries, where healthcare resources can be constrained. Limited availability and affordability of essential inhaled medicines can further restrict effective disease management. Patients may also mistake persistent coughing or breathlessness for normal aging or temporary respiratory problems and delay seeking medical attention. Consequently, many individuals are diagnosed only after significant lung-function decline or hospitalization. Expanding primary-care screening, improving access to spirometry, increasing availability of affordable medicines, and strengthening healthcare-worker training are therefore critical to improving diagnosis and expanding the addressable COPD treatment market.

High Treatment Costs and Persistent Exposure to Risk Factors

The COPD market also faces challenges from the long-term cost of disease management and continued exposure to preventable risk factors. COPD is a chronic condition requiring ongoing treatment rather than a short course of therapy. Patients may need long-acting inhalers, combination medicines, oxygen therapy, pulmonary rehabilitation, vaccinations, and treatment for acute exacerbations. The financial burden can be particularly significant for patients in countries where respiratory medicines are expensive or inadequately reimbursed. At the same time, eliminating the underlying risk factors remains difficult. Tobacco exposure continues to be a major contributor, with smoking responsible for more than 70% of COPD cases in high-income countries, according to WHO. Household air pollution also affects approximately 2.1 billion people who cook with polluting fuels and inefficient stoves, creating continued respiratory exposure in many developing countries. Occupational exposure to dust, fumes, and chemicals can further increase risk. COPD is also associated with recurrent exacerbations and other chronic conditions, increasing healthcare utilization. Therefore, improving medicine affordability, strengthening reimbursement, expanding smoking-cessation programs, reducing air pollution, and improving access to clean cooking technologies remain essential for overcoming market and public-health challenges.

Chronic Obstructive Pulmonary Disease Product Launches Worldwide

• Ohtuvayre (ensifentrine) – Verona Pharma, USA (2024): FDA approved Ohtuvayre in June 2024 as a novel inhaled maintenance treatment for COPD, representing the first inhaled COPD therapy with a new mechanism of action in more than 20 years.
• Vilfuro-G – Lupin, India (2023): Lupin launched Vilfuro-G, a once-daily fixed-dose triple-combination dry-powder inhaler containing vilanterol, fluticasone furoate, and glycopyrronium bromide for moderate-to-severe COPD.
• Tiotropium Bromide Inhalation Powder – Lupin, USA (2023): Lupin launched Tiotropium Bromide Inhalation Powder 18 mcg/capsule in the U.S. as a generic equivalent to Spiriva HandiHaler for COPD treatment.
• Triple-Combination Inhalation Aerosol – AstraZeneca, India (2023): AstraZeneca received Indian regulatory approval to market a triple combination of budesonide, glycopyrrolate, and formoterol fumarate as a pressurized metered-dose inhaler for COPD maintenance treatment.
• Symbicort Aerosphere – AstraZeneca, USA (2023): The FDA approved budesonide/formoterol 160/4.8 mcg in the Symbicort Aerosphere formulation as a maintenance treatment for COPD in April 2023.
• Foracort G Inhaler – Cipla, India (2024): Cipla introduced Foracort G, a triple-combination inhaler containing glycopyrrolate, formoterol, and budesonide, expanding its respiratory portfolio for COPD management.
• Glycohale FB Inhaler – Cipla, India (2024): Cipla launched Glycohale FB, a dry-powder triple combination of formoterol, budesonide, and glycopyrronium, for COPD treatment in India.
• Voltido Trio Inhaler – Cipla, India (2025): Cipla expanded its respiratory portfolio with Voltido Trio, combining fluticasone furoate, umeclidinium, and vilanterol for improved lung-function management in COPD.
• PEPAIR OPEP Device – Zydus Lifesciences, India (2026): Zydus introduced PEPAIR, a drug-free handheld oscillating positive expiratory pressure (OPEP) device designed to help loosen and clear mucus in people with chronic respiratory conditions, including COPD.
• Trelegy Ellipta – GSK, India (2022): GSK launched Trelegy Ellipta, a once-daily single-inhaler triple therapy containing fluticasone furoate, umeclidinium, and vilanterol, becoming the first single-inhaler triple therapy launched in India for COPD.

Chronic Bronchitis Market

The chronic bronchitis market is expanding as smoking, occupational exposure to pollutants, and aging populations continue to contribute to persistent respiratory symptoms and COPD-related disease. Increasing diagnosis and awareness are supporting demand for long-term therapies, including long-acting bronchodilators, inhaled corticosteroids, and fixed-dose combination treatments. Advances in pulmonary-function testing, digital spirometry, and remote monitoring are also improving disease detection and enabling more personalized management. Pharmaceutical companies are investing in innovative anti-inflammatory therapies, mucolytics, and other treatments designed to reduce airway inflammation, mucus production, and exacerbations. Healthcare providers are increasingly implementing guideline-based treatment pathways to improve medication adherence and reduce acute respiratory events. The continuing burden of tobacco smoke and air pollution remains a major concern, particularly in densely populated and industrialized regions. In addition, seasonal respiratory infections can worsen symptoms and increase healthcare utilization among vulnerable patients. As awareness of chronic respiratory disease increases and healthcare systems focus on reducing exacerbations and hospitalizations, demand for chronic bronchitis therapies, diagnostic solutions, and long-term monitoring technologies is expected to remain strong.

Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

The COPD drugs market is witnessing sustained growth because of the increasing global disease burden and the need for continuous maintenance treatment. Long-acting bronchodilators, including long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs), remain important components of COPD management, while LABA/LAMA and selected inhaled corticosteroid-containing combinations provide additional treatment options for appropriate patients. According to the WHO, COPD caused approximately 3.4 million deaths globally in 2023, highlighting the substantial need for effective long-term disease management.  Pharmaceutical innovation is increasingly focused on improving symptom control, reducing exacerbations, and simplifying treatment regimens. Smart inhalers and connected devices can support medication adherence and monitoring, while research into targeted therapies may expand options for patients with severe disease or specific inflammatory characteristics. Healthcare providers and payers are also emphasizing evidence-based maintenance therapy to reduce exacerbations and avoid preventable hospitalizations. Expansion of distribution through hospitals, community pharmacies, and digital healthcare channels is improving patient access. Continued investment in respiratory drug R&D, combination therapies, and personalized treatment approaches is expected to support market growth over the coming years.

Hospital Pharmacies Market for COPD Treatments

Hospital pharmacies are a critical component of the COPD treatment ecosystem, supporting the availability and appropriate use of medicines and respiratory therapies for both hospitalized and outpatient patients. Severe COPD exacerbations can require emergency treatment and hospitalization, increasing demand for bronchodilators, corticosteroids, nebulized medicines, antibiotics when clinically indicated, oxygen-related therapies, and other supportive treatments. Hospital pharmacists contribute to medication reconciliation, patient counseling, discharge planning, and inhaler-use education, helping patients understand correct administration and improve adherence after leaving the hospital. Healthcare institutions are increasingly implementing standardized COPD management pathways based on clinical guidelines to improve treatment consistency and reduce avoidable readmissions. Digital inventory management, automated dispensing, electronic prescribing, and formulary optimization are further improving pharmacy efficiency and medicine availability. Hospitals also play an important role in managing patients with severe or complicated COPD who require specialist respiratory care and multiple medications. As healthcare systems increasingly prioritize reducing exacerbations, improving medication adherence, and supporting transitions from hospital to home care, hospital pharmacies are expected to maintain an important role in COPD management. Growing adoption of advanced respiratory therapies and integrated digital healthcare solutions will further strengthen this segment.

United States Chronic Obstructive Pulmonary Disease Market

United States COPD market is supported by a substantial disease burden, advanced healthcare infrastructure, and rapid adoption of digital respiratory technologies. According to the CDC, more than 16 million U.S. adults have been diagnosed with COPD, while millions of additional cases may remain undiagnosed.  This large patient population creates sustained demand for inhaled bronchodilators, combination therapies, pulmonary diagnostics, oxygen equipment, and rehabilitation services. The country’s well-established healthcare system also facilitates the adoption of advanced spirometry, connected inhalers, remote patient monitoring, and AI-supported respiratory diagnostics. Furthermore, strong pharmaceutical and medical-device R&D capabilities contribute to continued development of novel COPD therapies and digital solutions. FDA approvals of new respiratory medicines and devices provide additional opportunities for market expansion. Growing emphasis on early diagnosis, medication adherence, reduction of COPD exacerbations, and home-based disease management is encouraging healthcare providers to adopt connected technologies. In addition, favorable reimbursement for selected remote monitoring and chronic-care services can support technology uptake. With a large treated and potentially undiagnosed population, high healthcare expenditure, and strong innovation capabilities, the U.S. is expected to remain one of the most influential markets for COPD treatment and management technologies.

Germany Chronic Obstructive Pulmonary Disease Market

Germany COPD market is driven by its comprehensive healthcare system, aging population, established reimbursement structure, and increasing emphasis on early respiratory disease management. COPD represents an important public-health burden in the country, particularly among older adults and people with a history of tobacco exposure. Germany’s healthcare infrastructure provides broad access to pulmonary function testing, specialist consultations, inhaled medicines, pulmonary rehabilitation, and chronic disease-management services. Increasing use of long-acting bronchodilators, combination inhalers, digital health applications, and advanced diagnostic technologies is creating additional opportunities for market development. Germany’s statutory health insurance system plays an important role in supporting patient access to medically necessary treatments and services. At the same time, healthcare providers are increasingly focusing on improving medication adherence and reducing exacerbations and hospital admissions through continuous disease monitoring. Digital respiratory solutions, including connected inhaler technologies and remote monitoring platforms, can support these objectives by providing additional information on medication use and symptoms. The country’s strong research environment and adoption of evidence-based clinical practices further encourage innovation. As smoking-related disease and population aging continue to influence COPD prevalence, demand for effective maintenance therapies, diagnostics, rehabilitation, and digital management solutions is expected to remain strong.

China Chronic Obstructive Pulmonary Disease Market

China COPD market has significant growth potential because of the country’s large population and substantial burden of chronic respiratory disease. A systematic review published in 2025 estimated that the pooled prevalence of COPD among Chinese adults aged 40 years and older was approximately 12.1% through 2024, highlighting the scale of the treatment opportunity.  This high prevalence is generating demand for long-acting bronchodilators, combination inhalers, pulmonary-function testing, oxygen therapy, rehabilitation, and other long-term management solutions. China’s healthcare system is also placing greater emphasis on early detection and improved COPD management at primary-care and community-health levels. Expanding access to spirometry and respiratory specialists can help identify patients earlier and improve treatment rates. In addition, high smoking prevalence, particularly among men, combined with exposure to ambient and household air pollution, continues to contribute to respiratory disease risk. Urbanization and growing healthcare expenditure are further supporting investment in modern respiratory-care technologies. Pharmaceutical manufacturers are expanding their presence in the Chinese respiratory market, while digital health platforms and connected monitoring solutions are creating new opportunities for improving adherence and disease monitoring. Continued healthcare reforms, improving reimbursement, and greater public awareness are expected to support the expansion of China’s COPD market.

Saudi Arabia Chronic Obstructive Pulmonary Disease Market

Saudi Arabia COPD market is developing as the Kingdom expands its respiratory healthcare infrastructure and strengthens prevention, diagnosis, and long-term management of chronic diseases. Smoking and environmental exposure remain important respiratory-health concerns, while obesity, population aging, and other chronic conditions can increase healthcare requirements among patients with COPD. Greater awareness of respiratory symptoms and smoking-cessation initiatives is encouraging patients to seek medical evaluation and treatment. Hospitals and specialized clinics are increasingly equipped with modern spirometry, pulmonary-function testing, inhaled drug therapies, and digital health technologies to support diagnosis and ongoing disease management. Saudi Arabia’s Vision 2030 healthcare transformation is also encouraging investment in healthcare modernization, digital health, prevention, and improved access to specialized services. These developments create opportunities for long-acting bronchodilators, combination inhalers, connected respiratory devices, remote monitoring, and pulmonary rehabilitation. Healthcare providers are increasingly emphasizing early diagnosis and reducing avoidable hospitalizations through better chronic disease management. As healthcare infrastructure expands beyond major urban centers and digital-health adoption increases, access to COPD services is expected to improve. Consequently, rising awareness, healthcare modernization, and continued investment in advanced respiratory-care technologies are expected to support steady growth of the Saudi Arabian COPD market.

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation

Types

• Chronic Bronchitis
• Emphysema

Treatment Types

• Drugs
• Oxygen Therapy
• Surgery
• Others

Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis

• AstraZeneca
• Pfizer, Inc.
• GlaxoSmithKline plc.
• Novartis AG
• Astellas Pharma Inc.
• Abbott Laboratories
• Boehringer Ingelheim International GmbH
• Almirall

Report Details:

Customization Services available

• Analysis of Market Size and Its Segments
• More Company Profiles (Upto 10 without any additional cost):
• Additional Countries (Other than mentioned Countries):
• Region/Country Specific Reports:
• Market Entry Strategy:
• Region-Specific Market Dynamics:
• Regional Market Share Analysis:
• Trade Analysis:
• Production Insights:
• Others Customized Requests:

For more information contact our analysts.

Need More Assistance?

• Talk to our analysts to get more precious information on the current market trends.
• Include more countries and segments and customize the report based on the final requirement.
• Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
• Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.